EQT life science
EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
Rankings
Industries / Tags:
Detailed EQT life science Information
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Acquirer
Geographic Data
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
4,837,703Website Global Rank
2,148Website Monthly Traffic
Twitter Followers
Description
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2003 | Affectis Pharmaceuticals | Series A | - |
| 2/2010 | Promethera Biosciences | Series A | 7.3M |
| 11/2011 | Harvest Automation | Series B | 7.9M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2007 | Isto Technologies | Series E | 0 |
| 4/2000 | NewBiotics | Venture Round | 6.3M |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 5/2011 | Cobalt Technologies | Series D | 0 |
| 5/2019 | DNA Script | Series B | 38.5M |
| 1/2011 | Nexstim | Venture Round | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 10/2015 | Luxendo | Series A | 0 |
| 8/2018 | Artios Pharma | Series B | 0 |
| 9/2019 | Pharvaris | Series B | 66M |
| 1/2009 | BMEYE | Series A | - |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 7/2020 | Cybin | Series B | 0 |
| 3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 4/2004 | NewBiotics | Series E | 4.6M |
| 10/1999 | Devgen | Series B | 24.7M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 8/2021 | Visus Therapeutics | Equity | 20M |
| 6/2020 | OneProjects | Series A | 12.4M |
| 1/2010 | Harvest Automation | Series A | 4M |
| 4/2014 | Heart Metabolics | Series A | 20M |
| 1/2007 | 4-Antibody AG | Series A | 18.4M |
| 10/2012 | Cobalt Technologies | Venture Round | 5M |
| 3/2019 | SNIPR Biome | Series A | 50M |
| 12/2014 | Xeltis | Series B | 33.5M |
| 4/2005 | DNage | Series A | 1.9M |
| 1/2016 | Pharvaris | Series A | 16.3M |
| 4/2006 | Pronota | Series A | 7.8M |
| 1/2010 | Merus | Series B | 0 |
| 4/2012 | Cobalt Technologies | Venture Round | 2.9M |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 5/2018 | Rainier Therapeutics | Series B | 20M |
| 2/2007 | Prosensa | Series A | 18M |
| 9/2010 | Harvest Automation | Series A | 1.3M |
| 10/2013 | Harvest Automation | Series C | 11.8M |
| 5/2003 | Santarus | Series D | 51.4M |
| 7/2017 | Simplify Medical | Series B | 21M |
| 2/2018 | Simplify Medical | Series B | 23M |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2009 | Kreatech Diagnostics | Venture Round | 0 |
| 10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
| 9/2007 | Nexstim | Venture Round | 10.9M |
| 4/2016 | Onward | Series A | 29.5M |
| 11/2017 | Xeltis | Series C | 53M |
| 5/2008 | Asoyia | Venture Round | 4M |
| 2/2022 | Perfuze | Series A | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 3/2010 | Seahorse Bioscience | Series D | 5M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 12/2006 | BMEYE | Series A | - |
| 1/2012 | Pronota | Series C | 4.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 2/2009 | ActoGeniX | Private Equity Round | 17.4M |
| 2/2007 | ActoGeniX | Venture Round | 26.1M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
| 11/2012 | Kiadis Pharma | Venture Round | 0 |
| 7/2001 | NewBiotics | Series C | 0 |
| 9/2016 | Vivasure Medical | Series C | 18.3M |
| 9/2017 | Immunic Therapeutics | Series A | 11.9M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
| 7/2003 | PamGene | Series B | 11.3M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
| 11/2014 | Curetis | Series B | 0 |
| 7/2020 | DNA Script | Series B | 50M |
| 7/2002 | Scion Pharmaceuticals | Series B | 0 |
| 8/2006 | Pronota | Series A | 10.6M |
| 10/2021 | DNA Script | Series C | 0 |
| 11/2009 | Vivoryon Therapeutics | Series B | 0 |
| 1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
| 8/2007 | BioProcessors | Series C | 10M |
| 12/2018 | XyloCor Therapeutics | Series A | 17M |
| 1/2012 | Prosensa | Venture Round | 0 |
| 10/2012 | Affimed | Series D | 20.1M |
| 7/2009 | Pasteuria Bioscience | Series B | 0 |
| 12/2009 | Curetis | Series A | 27.9M |
| 2/2019 | Arvelle Therapeutics | Series A | 0 |
| 12/2000 | PamGene | Series A | 6.2M |
| 3/2021 | XyloCor Therapeutics | Series A | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 10/2021 | OneProjects | Series A | 8M |
| 5/2023 | VarmX | Series B | 0 |
| 2/2018 | Merus | Post-IPO Equity | 55.8M |
| 4/2007 | Affimed | Series B | 32M |
| 8/2016 | Rotation Medical | Series B | 12M |
| 7/2014 | Rotation Medical | Series B | 27.2M |
| 1/2021 | Neurent Medical | Series B | 0 |
| 6/2015 | Neuravi | Series B | 21.5M |
| 6/2007 | Kiadis Pharma | Venture Round | 0 |
| 7/2021 | Xilis | Series A | 0 |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 12/2021 | AviadoBio | Series A | 0 |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 1/2017 | Binx Health | Series D | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 3/2023 | QurAlis | Series B | 0 |
| 12/2015 | Xeltis | Series B | 3.3M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 3/2015 | Cardiac Dimensions | Equity | 15.2M |
| 10/2021 | Egle Therapeutics | Series A | 0 |
| 3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 8/2016 | Mint Solutions | Series B | 5.6M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 7/2020 | ViCentra | Venture Round | 0 |
| 9/2018 | Endotronix | Series D | 0 |
| 9/2020 | Cardiac Dimensions | Series C | 17.5M |
| 10/2008 | Cobalt Technologies | Series C | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 8/2021 | T-knife | Series B | 110M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 7/2014 | Mint Solutions | Series A | 6M |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 4/2014 | Binx Health | Series B | 0 |
| 4/2021 | Onward | Venture Round | 0 |
| 3/2017 | Rainier Therapeutics | Series B | 30M |
| 7/2020 | VarmX | Series B | 36.3M |
| 11/2016 | OxThera | Series D | 34.1M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 1/2010 | Kreatech Diagnostics | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 4/2023 | Evommune | Series B | 50M |
| 9/2014 | Affimed | Series E | 0 |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 1/2016 | Rainier Therapeutics | Series A | 13M |
| 4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
| 6/2011 | Mendor | Series B | 11.7M |
| 1/2016 | ViCentra | Series B | 10.9M |
| 9/2016 | Immunic Therapeutics | Series A | 19.6M |
| 5/2020 | Arvelle Therapeutics | Series A | 0 |
| 8/2007 | FlowCardia | Series C | 0 |
| 4/2023 | Evommune | Series B | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 2/2022 | Perfuze | Series A | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 12/2021 | AviadoBio | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
